Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
27 Results for "
LDHB
" in MedChemExpress (MCE) Product Catalog:
Products (27)
27 Results for "LDHB" in MCE Product Catalog:
20
20 Publications Verification
Target:
Research Areas:
Cardiovascular Disease Infection Inflammation/Immunology Cancer
(R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
18
18 Cited Publications
Cat. No.: HY-W040118
CAS No.: 568-80-9
Target:
Research Areas:
Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .
9
9 Cited Publications
Research Areas:
GNE-140 racemate is a racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and also a tautomer of GNE-140 (HY-118241). GNE-140 racemate is an orally active lactate dehydrogenase inhibitor, with an IC50 of 3 nM against human LDHA and an IC50 of 5 nM against LDHB. GNE-140 racemate reduces the phosphorylation level and total protein expression of p38 MAPK, and inhibits EGF-induced AKT phosphorylation. GNE-140 racemate decreases lactate production, regulates glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, increases extracellular pH, inhibits cell proliferation, migration and invasion, and induces caspase-3 activation and ROS accumulation. GNE-140 racemate can be used in research related to breast cancer, cystic fibrosis and pancreatic cancer .
8
8 Cited Publications
Target:
Research Areas:
AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism .
8
8 Cited Publications
Cat. No.: HY-147216A
Purity: 99.68%
Target:
Research Areas:
AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism .
3
3 Cited Publications
Target:
Research Areas:
LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
1
1 Cited Publications
Cat. No.: HY-P70265
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LDHB; LDH-H; Lactate Dehydrogenase B; Epididymis Secretory Protein Li 281; L-Lactate Dehydrogenase B Chain; Testicular Secretory Protein Li 25; Renal Carcinoma Antigen NY-REN-46; Lactate Dehydrogenase H Chain; LDH Heart Subunit; L-Lactate Dehydrogenase; H
Species:
Human
Source:
E. coli
Target:
Research Areas:
MS6105 is a PROTAC degrader targeting LDHA and LDHB, with DC50 values of 38 nM and 74 nM for degrading LDHA and LDHB in PANC-1 cells, respectively, and no hook effect is observed at high concentrations. MS6105 inhibits the proliferation of pancreatic cancer cells, and no obvious toxicity is observed after intraperitoneal administration in mice. MS6105 can be used for pancreatic cancer-related research .
Target:
Research Areas:
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
Target:
Research Areas:
(S)-GNE-140 (Compound 30-S) is the S enantiomer of GNE-140 (HY-118241). (S)-GNE-140 is a potent inhibitor of human LDHA and LDHB, with IC50 values of 55 nM and 140 nM, respectively. (S)-GNE-140 exerts its inhibitory effect by non-competitively binding to NADH and occupying the LDH pyruvate site, but its activity is weaker than that of the R enantiomer. (S)-GNE-140 can be used for cancer research .
Cat. No.: HY-176798
CAS No.: 1964516-64-0
Research Areas:
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
Cat. No.: HY-RS07572
Target:
Research Areas:
LDHB Human Pre-designed siRNA Set A contains three designed siRNAs for LDHB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23432
Target:
Research Areas:
Ldhb Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldhb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS16989
Target:
Research Areas:
Ldhb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldhb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-162629
CAS No.: 3043790-15-1
Target:
Research Areas:
LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC50s of 72 nM and 1.2 Μm, respectively .
Cat. No.: HY-P86602
Synonyms: LDHA; PIG19; LDHB; LDHC; LDH3; LDHX; L-lactate dehydrogenase A chain; LDH-A; Cell proliferation-inducing gene 19 protein; LDH muscle subunit; LDH-M; Renal carcinoma antigen NY-REN-59; L-lactate dehydrogenase B chain; LDH-B; LDH heart subunit; LDH-H; Renal carcinoma antigen NY-REN-46; L-lactate dehydrogenase C chain; LDH-C; Cancer/testis antigen 32; CT32; LDH testis subunit; LDH-X;
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
